THE ORAL MICROBIOME IN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA TREATED WITH IXAZOMIB-THALIDOMIDE-DEXAMETHASONE (AGMT_MM-1 PHASE II TRIAL)

EHA Library, Heinz Ludwig, 293535

SPORADIC LATE ONSET NEMALINE MYOPATHY WITH MONOCLONAL PROTEIN IS A MALIGNANCY AND SHOULD BE TREATED WITH CHEMOTHERAPY-BASED APPROACH

EHA Library, Rouslan Kotchetkov, 293536

DREAMM-2 PIVOTAL STUDY: ANALYSIS OF THE LYOPHILIZED PRESENTATION COHORT OF SINGLE-AGENT BELANTAMAB MAFODOTIN FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, PAUL RICHARDSON, 293537

POST-AUTHORIZATION SAFETY STUDY COMPARING LENALIDOMIDE-BASED TREATMENT VS NON−LENALIDOMIDE-BASED TREATMENT IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Barbara Gamberi, 293538

DOUBLE AND TRIPLE HIT MULTIPLE MYELOMA: NEW ULTRA HIGH-RISK ENTITIES?

EHA Library, Aleksandra Sretenovic, 293541

EFFECT OF PROLONGED TREATMENT WITH CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

EHA Library, Cécile Gruchet, 293542

GAIT SPEED AND HANDGRIP TEST TO ASSESS PHYSICAL FRAILTY IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Sotirios Bristogiannis, 293543

CLINICAL PHENOTYPES AND BLOOD FEATURES ASSOCIATED WITH CLONAL MYELOPOIESIS IN THE UK BIOBANK COHORT: ASXL1 MUTATIONS ARE STRONGLY ASSOCIATED WITH SMOKING HISTORY

EHA Library, Nick Cross, 293546

EXPLOITING THE CD47-SIRPΑ MACROPHAGE CHECKPOINT TO CONTROL POLYCYTHEMIA VERA

EHA Library, Veronika Lysenko, 293547

IN SYSTEMIC MASOCYTOSIS, MIDOSTAURIN TARGETS BOTH KIT AND AURORA KINASE A REVERTING H3K36ME3 DEFICIENCY AND SYNERGIZES WITH NILOTINIB AND DASATINIB

EHA Library, Manuela Mancini, 293548

CLONAL HETEROGENEITY AND EVOLUTION OF MPN REVEALED BY SINGLE-CELL RNA/DNA SEQUENCING

EHA Library, Xingxing Qi, 293549

NECROPTOTIC SIGNALING IS ENHANCED IN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) FROM PATIENTS WITH MYELOFIBROSIS (MF)

EHA Library, Veronika Dill, 293556

HOMOZYGOUS CALRETICULIN MUTATIONS AFFECT CHAPERONE FUNCTION AND PERTURB THE GLYCOPROTEOME

EHA Library, Patrick Schürch, 293557

EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS

EHA Library, Ciro Rinaldi, 293560

FREQUENCY OF BCR-ABL1, JAK2V617F, MPLW515L/K AND CALR TYPE 1,2 MUTATIONS CO-OCCURENCE IN CML PATIENTS UNDERGOING TKI THERAPY AND ITS POSSIBLE PROGNOSTIC VALUE

EHA Library, Adhamjon Abdullaev, 293562

MOLECULAR CHARACTERISATION OF THE DER(6)T(1;6) IN MYELOID NEOPLASMS

EHA Library, Sophie Laird, 293563

PHENFORMIN INCREASES THE FREQUENCIES OF LSK, MULTIPOTENT PROGENITOR, AND MYELOID PROGENITOR IN JAK2V617F MURINE MODEL OF MYELOPROLIFERATIVE NEOPLASM

EHA Library, Antonio Bruno Alves-Silva, 293564

ROLE OF TRAINED IMMUNITY AND IMMUNOMETABOLISM IN THE PATHOGENESIS OF ERDHEIM-CHESTER DISEASE

EHA Library, Giulio Cavalli, 293567

A PHASE 2 STUDY OF BOMEDEMSTAT (IMG-7289), A LYSINE-SPECIFIC DEMETHYLASE-! (LSD!) INHIBITOR, FOR THE TREATMENT OF LATER-STAGE MYELOFIBROSIS (MF)

EHA Library, Kristen Pettit, 293569

NAVITOCLAX IN COMBINATION WITH RUXOLITINIB IN PATIENTS WITH PRIMARY OR SECONDARY MYELOFIBROSIS: A PHASE 2 STUDY

EHA Library, Claire Harrison, 293570

RESULTS FROM PIONEER: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY OF AVAPRITINIB IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS

EHA Library, Cem Akin, 293571

CPI-0610, BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS 'ADD-ON' TO RUXOLITINIB (RUX), IN ADVANCED MYELOFIBROSIS PATIENTS WITH SUBOPTIMAL RESPONSE: UPDATE OF MANIFEST PHASE 2 STUDY

EHA Library, Srdan Verstovsek, 293572

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR TREATMENT NAÏVE MYELOFIBROSIS PATIENTS: UPDATE FROM MANIFEST PHASE 2 STUDY

EHA Library, John Mascarenhas, 293573

ROPEGINTERFERON ALPHA-2B IS EFFICACIOUS AND REDUCES VARIANT TET2 ALLELE BURDEN IN PATIENTS WITH POLYCYTHAEMIA VERA AND TET2 MUTATION: GENETIC ANALYSIS OF PHASE III PROUD-PV/CONTINUATION-PV STUDIES

EHA Library, Robert Kralovics, 293574

CO-MUTATIONS AND NON-CANONICAL DRIVER MUTATIONS IDENTIFIED BY NEXT GENERATION SEQUENCING IN MYELOPROLIFERATIVE NEOPLASMS REVEAL SIGNIFICANT OPPORTUNITIES FOR IMPROVED DIAGNOSTIC PRACTICE

EHA Library, Ella Thompson, 293576

CLINICIAL, MORPHOLOGICAL AND GENETIC EVIDENCE FOR TWO INDEPENDENT DISEASES IN PATIENTS CONCURRENTLY POSITIVE FOR JAK2 V617F AND KIT D816V

EHA Library, Juliana Schwaab, 293577

INTERIM ANALYSIS OF A PHASE II TRIAL (HOVON-134) IN MYELOFIBROSIS PATIENTS (PRIMARY, POST-ET OR POST PV-MF) TREATED WITH THE JAK2 INHIBITOR PACRITINIB BEFORE RIC ALLOGENEIC STEM CELL TRANSPLANTATION

EHA Library, Peter te Boekhorst, 293578

CHRONIC NEUTROPHILIC LEUKEMIA AND ATYPICAL CHRONIC MYELOID LEUKEMIA ARE HIGLY OVERLAPPING DISORDERS. RESULTS FROM AN INTERNATIONAL BRITISH-SPANISH STUDY

EHA Library, Gonzalo Carreño Gómez-Tarragona, 293579

MYELOPROLIFERATIVE NEOPLASMS-UNCLASSIFIABLE: CLINICOPATHOLOGICAL CHARACTERISATION AND OUTCOME ANALYSIS

EHA Library, Paul Deschamps, 293581

PHENOTYPIC DIFFERENCES AND PROGNOSTIC IMPACT OF SIGNALING MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Evandro Bezerra, 293582

LONG-TERM SAFETY OF FEDRATINIB IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF)

EHA Library, Animesh Pardanani, 293585

TELOMERASE ACTIVITY, TELOMERE LENGTH AND HTERT EXPRESSION CORRELATE WITH CLINICAL OUTCOMES IN HIGHER-RISK MYELOFIBROSIS (MF) RELAPSED/REFRACTORY (R/R) TO JANUS KINASE INHIBITOR TREATED WITH IMETELSTAT

EHA Library, John Mascarenhas, 293587

IMETELSTAT TREATMENT RESULTS IN CLINICAL BENEFITS, INCLUDING IMPROVED OVERALL SURVIVAL, IN PATIENTS WITH HIGHER-RISK TRIPLE-NEGATIVE MYELOFIBROSIS RELAPSED/REFRACTORY TO JANUS KINASE INHIBITORS (JAKI)

EHA Library, Jean-Jacques KILADJIAN, 293590

HAEMATOLOGICAL MALIGNANCIES IN RELATIVES OF PATIENTS AFFECTED WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Daniele Vanni, 293595

MUTATIONAL GENOMIC PROFILE OF TRIPLE-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS USING NEXT-GENERATION SEQUENCING

EHA Library, Sara Duarte, 293597

PATIENT-REPORTED PHYSICAL, EMOTIONAL AND ECONOMIC IMPACT OF MYELOPROLIFERATIVE NEOPLASMS IN AN EXPANSION OF THE MPN LANDMARK SURVEY

EHA Library, Guray Saydam, 293601

REAL-WORLD SURVIVAL IN ELDERLY PATIENTS WITH MYELOFIBROSIS IN THE UNITED STATES: PRE- VS POST-RUXOLITINIB APPROVAL

EHA Library, Srdan Verstovsek, 293609

PREGNANCY OUTCOMES IN PATIENTS WITH PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RECENT, EXTENDED RETROSPECTIVE ANALYSIS

EHA Library, Bozena Sokolowska, 293610

TREATMENT AND DISEASE MANAGEMENT PRACTICES IN PATIENTS WITH MPNS IN 6 COUNTRIES: AN EXPANSION OF THE MPN LANDMARK SURVEY

EHA Library, Cheng-Shyong Chang, 293612

REAL-WORLD SURVIVAL IN ELDERLY PATIENTS WITH MYELOFIBROSIS IN THE UNITED STATES: RUXOLITINIB EXPOSED VS UNEXPOSED

EHA Library, Srdan Verstovsek, 293613

IMPACT OF PLATELET COUNT ON THROMBOTIC RISK IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA WITH NORMAL LEUKOCYTE COUNT

EHA Library, Veronika Buxhofer-Ausch, 293614

SPLEEN STIFFNESS MEASUREMENT BY USING SHEAR-WAVE ELASTOGRAPHY AS A PREDICTOR OF PROGRESSION TO SECONDARY MYELOFIBROSIS

EHA Library, Omer Ekinci, 293616

DOSE-INTENSIFICATION IN EARLY UNFAVORABLE HODGKIN LYMPHOMA: LONG-TERM FOLLOW UP OF THE GERMAN HODGKIN STUDY GROUP (GHSG) HD14 TRIAL

EHA Library, Bastian Von Tresckow, 293619

NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY OR TARGETED THERAPY IN THE TREATMENT OF PATIENTS WITH RELAPSED AND REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Liudmila Fedorova, 293620

THE COMBINED PROGNOSTIC ROLE OF INTERIM 18FDG-PET AND TARC IN HODGKIN LYMPHOMA

EHA Library, Laszlo Pinczes, 293622

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY FOR STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 4-YEAR UPDATE OF THE ECHELON-1 STUDY

EHA Library, Marco Picardi, 293624

OBJECTIVE RESPONSE RATES AND QUALITY OF LIFE CHANGES IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA (RR HL) RECEIVING BRENTUXIMAB VEDOTIN AS >2 LINE OF TREATMENT IN THE REAL WORLD SETTING

EHA Library, Tatyana Ionova, 293628

PATIENT CHARACTERISTICS, TREATMENT PATTERNS, AND CLINICAL OUTCOMES IN THE FRONTLINE TREATMENT OF ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA IN ITALY, SPAIN, AND ISRAEL

EHA Library, Abraham Avigdor, 293632

SECONDARY MALIGNANCIES IN HODGKIN LYMPHOMA SURVIVORS: A SINGLE CENTER EXPERIENCE

EHA Library, Maria Pina Simula, 293636

TREATMENT PATHWAYS AND CLINICAL OUTCOMES OF PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA IN LATIN AMERICA: INTERIM RESULTS FROM AN INTERNATIONAL, MULTICENTRE, RETROSPECTIVE STUDY

EHA Library, Amado Karduss Urueta, 293637

24-H URINE: IS IT REALLY NECESSARY FOR MULTIPLE MYELOMA FOLLOW-UP?

EHA Library, Joao Pedro Barreto, 293531

HEMATOLOGIC MALIGNACIES AND GAMMOPATHIES IN GAUCHER DISEASE TYPE 1

EHA Library, Maria Domenica Cappellini, 293533

MULTIPLE MYELOMA FRAILTY POPULATION IN SPAIN: PRELIMINARY ANALYSIS OF THE INSIGHT MM REGISTRY

EHA Library, Noemi Puig, 293534

A REAL-WORLD COMPARATIVE EFFECTIVENESS ANALYSIS OF PROTEASOME INHIBITOR-BASED REGIMENS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA UTILIZING A NATIONWIDE DATABASE IN JAPAN

EHA Library, Hirokazu Tanaka, 293539

THE RELATIONSHIP BETWEEN NEGATIVITY OF SERUM FREE LIGHT CHAINS, MINIMAL RESIDUAL DISEASE, AND OVERALL SURVIVAL IN PATIENTS WITH SYMPTOMATIC MULTIPLE MYELOMA

EHA Library, Kentaro Narita, 293540

AUTOLOGOUS STEM CELL TRANSPLANT AFTER INDUCTION THERAPY IMPROVES OUTCOME IN INITIALLY INELIGIBLE PATIENTS WITH SYSTEMIC IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS

EHA Library, Ilaria Cappuccio, 293544

SURVIVAL TRENDS IN MULTIPLE MYELOMA AFTER AUTOLOGOUS HEMATOPIETIC STEM CELL TRANSPLANTATION

EHA Library, Samer A. Srour, 293545

SETD2 PROTEIN LEVELS ARE A NOVEL PREDICTOR OF OVERALL SURVIVAL IN SYSTEMIC MASTOCYTOSIS

EHA Library, Michela Rondoni, 293550

IL-1RA LEVEL IN THE SERUM IS STRONGLY CORRELATED WITH THE JAK2V617F ALLELE BURDEN, MYELOFIBROSIS, SPLENOMEGALY AND SLAMF7HIGH CD16− MONOCYTES IN THE PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Takaaki Maekawa, 293552

HLA CLASS I GENOTYPE SHAPES JAK2 V617F DRIVEN LEUKEMOGENESIS

EHA Library, Velizar Shivarov, 293553

A NOVEL IN VITRO PLATFORM FOR THE PRIORITISATION AND VALIDATION OF INHIBITORS OF BONE MARROW FIBROSIS USING HUMAN BONE MARROW (BM) STROMAL CELLS

EHA Library, Michela Colombo, 293554

NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES TO IDENTIFY POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME

EHA Library, Martina Barone, 293555

THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IS A CHEAP SURROGATE OF THE IMMUNESUPPRESSIVE MICROENVIRONMENT IN MYELOFIBROSIS AND MAY PREDICT RESPONSE TO RUXOLITINIB

EHA Library, Alessandra Romano, 293558

REWIRED CELL ENERGY METABOLISM IN A NOVEL KRAS-MUTATED HISTIOCYTOSIS CHARACTERIZED BY SEVERE SYNOVITIS

EHA Library, Giulio Cavalli, 293561

CLINICAL AND BIOLOGICAL FEATURES DISTINGUISH MYELOID DISEASES FROM MYELOID DISORDERS ASSOCIATED WITH AUTOIMMUNE DISEASES.

EHA Library, sara galimberti, 293565

CLINICAL SIGNIFICANCE OF MPL MUTATIONS IN ESSENTIAL THROMBOCYTEMIA PATIENTS: RISK ASSESMENT OF MYELOFIBROTIC TRANSFORMATION.

EHA Library, Rocío García-Serra, 293566

AVAPRITINIB INDUCES RESPONSES IN PATIENTS (PTS) WITH ADVANCED SYSTEMIC MASTOCYTOSIS (ADVSM), REGARDLESS OF PRIOR MIDOSTAURIN THERAPY

EHA Library, Jason Gotlib, 293568

CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN (BET) INHIBITOR, AS MONOTHERAPY IN ADVANCED MYELOFIBROSIS PATIENTS REFRACTORY/INTOLERANT TO JAK INHIBITOR: UPDATE FROM PHASE 2 MANIFEST STUDY

EHA Library, Moshe Talpaz, 293580

METFORMIN AND STATINS DO NOT LOWER MYELOFIBROSIS INCIDENS, OVERALL SURVIVAL OR RISK OF LEUKEMIC TRANFORMATION: A DANISH NATIONWIDE COHORT STUDY

EHA Library, Daniel Kristensen, 293583

SECOND PRIMARY MALIGNANCY IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB

EHA Library, Francesca Palandri, 293586

MYELOABLATIVE FLUDARABINE AND BUSULFAN REGIMEN IN MYELOFIBROSIS: LONG TERM OUTCOMES AND ANALYSIS OF PROGNOSTIC FACTORS

EHA Library, Jacinth Joseph, 293588

KIDNEY DYSFUNCTION IS ASSOCIATED WITH INCREASED THROMBOSIS BUT NOT SEVERE BLEEDING EVENTS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS: AN ANALYSIS FROM THE GERMAN GSG-MPN BIOREGISTRY

EHA Library, Steffen Koschmieder, 293589

THE WHO SUBCATEGORY 'MYELOID/LYMPHOID NEOPLASMS WITH EOSINOPHILIA AND REARRANGEMENT OF PDGFRA, PDGFRB OR FGFR1, OR PCM1-JAK2' REVISITED IN 74 PATIENTS: LACK OF EOSINOPHILIA AND PRESENCE OF MONOCYTOSIS

EHA Library, Laurenz Steiner, 293591

MOMELOTINIB DOSE-INTENSITY IS MAINTAINED IN JAK INHIBITOR NAÏVE AND PREVIOUSLY JAK INHIBITOR TREATED INTERMEDIATE/HIGH RISK MYELOFIBROSIS PATIENTS

EHA Library, Vikas Gupta, 293592

USE OF NEXT GENERATION SEQUENCING GENE PANEL FOR IDIOPATHIC ERYTHROCYTOSIS IN A SINGLE CENTRE

EHA Library, Rebekah Williams, 293593

MYSEC-PROGNOSTIC MODEL AND PREVIOUS THROMBOTIC EVENTS PREDICT THE RISK OF THROMBOSIS IN POST POLYCYTHEMIA VERA AND POST ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A STUDY OF THE MYSEC GROUP

EHA Library, Barbara Mora, 293594

FAVORABLE OVERALL SURVIVAL WITH IMETELSTAT TREATMENT CORRELATES WITH OTHER CLINICAL BENEFITS IN INTERMEDIATE 2 OR HIGH RISK MYELOFIBROSIS RELAPSED/REFRACTORY TO JANUS KINASE INHIBITOR

EHA Library, John Mascarenhas, 293596

EARLY ONSET OF SPLEEN AND SYMPTOM RESPONSES WITH FEDRATINIB (FEDR) IN PATIENTS WITH INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF)

EHA Library, Francesco Passamonti, 293598

PULMONARY HYPERTENSION IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM: A SINGLE CENTER RETROSPECTIVE ANALYSIS OF 225 PATIENTS

EHA Library, Ik-Chan Song, 293599

OUTCOMES OF 99 PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM (MPN) ASSOCIATED SPLANCHNIC VEIN THROMBOSIS (SVT): FIRST REPORT FROM THE UK MASCOT REGISTRY

EHA Library, Hannah Brown, 293600

LONG TERM SAFETY OF MOMELOTINIB IN JAK INHIBITOR NAÏVE AND PREVIOUSLY JAK INHIBITOR TREATED INTERMEDIATE/HIGH RISK MYELOFIBROSIS PATIENTS

EHA Library, Claire Harrison, 293602

A POPULATION-BASED STUDY OF CHRONIC EOSINOPHILIC LEUKEMIA-NOT OTHERWISE SPECIFIED IN THE UNITED STATES: 2004-2015

EHA Library, Gordon Ruan, 293603

RUXOLITINIB IN PV PATIENTS RESISTANT AND/OR INTOLERANT TO HYDROXYUREA: INTERIM ANALYSIS OF A EUROPEAN MULTI-CENTRIC OBSERVATIONAL STUDY

EHA Library, Peter te Boekhorst, 293604

RUXOLITINIB COMBINED WITH PREDNISONE, THALIDOMIDE AND DANAZOL THERAPY IN MYELOFIBROSIS: A RETROSPECTIVE COHORT STUDY

EHA Library, Zhijian Xiao, 293605

MACHINE-LEARNING TO PREDICT HYDROXYUREA (HU) FAILURE AND INCIDENCE OF THROMBOEMBOLIC EVENTS (TES) WITH HU VS RUXOLITINIB SWITCH THERAPY IN POLYCYTHEMIA VERA PATIENTS

EHA Library, Srdan Verstovsek, 293606

CLINICAL-PATHOLOGICAL FEATURES OF TRIPLE-NEGATIVE ESSENTIAL THROMBOCHYTEMIA

EHA Library, Daniele Cattaneo, 293607

USE OF BIOSIMILAR ERYTHROPOIESIS STIMULANTING AGENTS FOR ANEMIA IN MYELOFIBROSIS: A MULTICENTER REAL-LIFE EXPERIENCE ON 40 PATIENTS

EHA Library, Elena Inzoli, 293608

USE OF NEXT-GENERATION SEQUENCING TO IDENTIFY MYELOID MUTATIONS ASSOCIATED WITH THROMBOTIC RISK IN PATIENTS WITH POLYCYTHEMIA VERA

EHA Library, Ruth Stuckey, 293611

RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE ANALYSIS OF REAL-WORLD PATIENTS IN ENGLAND, NORTHERN IRELAND AND WALES

EHA Library, James Russell, 293615

SECOND CANCER IN MYELOFIBROSIS TREATED WITH RUXOLITINIB: A 'REAL-LIFE' RETROSPECTIVE MULTICENTER EXSPERIENCE OF THE RETE EMATOLOGICA PUGLIESE (REP)

EHA Library, Erminia Rinaldi, 293617

IMPACT OF INTERIM PET ON HODGKIN LYMPHOMA TREATMENT OUTCOMES AND SURVIVAL IN CLINICAL PRACTICE.

EHA Library, Serena Zheng, 293618

NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA IN REAL CLINICAL PRACTICE: PROLONGED FOLLOW UP AND PROGNOSTIC FACTORS ANALYSIS

EHA Library, Lepik Kirill, 293621

EA(50)COPP-14 ± RADIOTHERAPY IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH ADVANCED STAGES OF CLASSICAL HODGKIN LYMPHOMA: RESULTS OF THE MODIFIED PROTOCOL «HLMOSCOW 1-3»

EHA Library, Gayane Tumyan, 293626

CARDIOVASCULAR DISEASES IN HODGKIN'S LYMPHOMA SURVIVORS: A SINGLE CENTER EXPERIENCE

EHA Library, Maria Pina Simula, 293627

PARANEOPLASTIC CEREBELLAR DEGENERATION ASSOCIATED WITH HODGKIN LYMPHOMA : A FRENCH RETROSPECTIVE COHORT

EHA Library, Kentin Queru, 293629

PROGNOSTIC VALUE OF THE FUNCTIONAL PARAMETERS: TOTAL METABOLIC TUMOR VOLUME (TMTV) AND TOTAL LESION GLYCOLYSIS (TLG) AT BASELINE [18F]FDG-PET/CT IN HODGKIN LYMPHOMA

EHA Library, Francisca Hernandez Mohedo, 293630

AN INTERNATIONAL, MULTICENTRE, RETROSPECTIVE STUDY TO DESCRIBE TREATMENT PATHWAYS AND OUTCOMES FOR CLASSICAL HODGKIN LYMPHOMA IN EAST ASIA: INTERIM RESULTS

EHA Library, Tae Min Kim, 293631

CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES IN CHILDREN AND YOUNG-ADULTS WITH HODGKIN'S LYMPHOMA: A KPHOG LYMPHOMA WORKING-PARTY, MULTICENTER, RETROSPECTIVE STUDY

EHA Library, Jae Min Lee, 293633

IMPACT OF NIVOLUMAB ON OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL) AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Philippe Armand, 293634

REAL-LIFE VALIDATION OF A SIMPLIFIED INTERNATIONAL PROGNOSTIC SCORE VERSION (IPS-3) IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA

EHA Library, Theodoros P. Vassilakopoulos, 293635